Delayed nivolumab‐induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case
| Autor: | Taiki Hayashi, Tsukasa Masuda, Koshiro Nishimoto, Suguru Shirotake, Masafumi Oyama, Hideyuki Kondo, Go Kaneko, Maki Todo, Takashi Okabe |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
hepatotoxicity medicine.drug_class Urology Case Report Case Reports lcsh:RC870-923 Gastroenterology metastatic renal cell carcinoma Thyroiditis Tyrosine-kinase inhibitor Pazopanib Renal cell carcinoma Internal medicine medicine pazopanib Hepatitis nivolumab business.industry Thyroid lcsh:Diseases of the genitourinary system. Urology medicine.disease Pathophysiology medicine.anatomical_structure Nivolumab business medicine.drug |
| Zdroj: | IJU Case Reports IJU Case Reports, Vol 2, Iss 5, Pp 272-275 (2019) |
| ISSN: | 2577-171X |
| Popis: | Introduction Pazopanib, a tyrosine kinase inhibitor, and nivolumab, an immune checkpoint inhibitor, are both considered to cause hepatotoxicity with different pathophysiology. We report a case in which a patient died of severe hepatotoxicity who was presumed to have been caused by the administration of nivolumab followed by pazopanib for metastatic renal cell carcinoma. Case presentation A 74-year-old male with metastatic renal cell carcinoma was treated with nivolumab as a third-line treatment. However, nivolumab was subsequently discontinued, as it caused severe thyroiditis. About 2 months after the final dose of nivolumab was administered, pazopanib was initiated as a fourth-line treatment. The patient suffered from lethal hepatic failure and died 18 days after the initiation of pazopanib treatment. An autopsy revealed that CD8-positive lymphocytes had infiltrated the thyroid gland and liver. Conclusion The patient was considered to have died of severe hepatic failure due to the aggravation of mild nivolumab-induced immune-related hepatitis by pazopanib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text